This former concept is currently being investigated in the ongoing ARCADIA trial[98], where apixaban is being compared to aspirin for the prevention of recurrent stroke in those identified with an ACM (at least one of the following; P-wave terminal force > 5000 mV ms in ECG lead V1, serum NT-proBNP > 250 pg/mL or left atrial diameter index 3 cm/m2). The gene discussed is NPPB; the disease is stroke disorder.